Enhancing Educational and Vocational Recovery in Adolescents and Young Adults With Early Psychosis Through Supported Employment and Education.

Schizophrenia Clinical Trial

— SEEearly  

Official title:

Enhancing Educational and Vocational Recovery in Adolescents and Young Adults With Early Psychosis Through Supported Employment and Education (SEE): A Randomized Controlled Trial. Acronym: SEEearly

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05824117
• Other study ID #: 470569697
• Secondary ID: DRKS00029660
• Status: Recruiting
• Phase: N/A
• Start date: October 18, 2022
• Est. completion date: March 31, 2025

Study information

• Verified date: April 2023
• Source: Charite University, Berlin, Germany
• Contact: Anna Willert, Dr. med.
• Phone: +4930130226001
• Email: anna.willert[@]charite.de
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Psychotic disorders often develop a chronic course with devastating consequences for individuals, families, and societies usually with first onset during adolescence and early adulthood. Early intervention programs, which provide intensive, phase specific, psychosocial, and pharmacological treatment for people in the first five years after the initial psychotic episode (early psychosis) can significantly improve the outcome and are therefore strongly recommended in national and international guidelines. However, most early intervention programs in people with early psychosis still focus on improving symptoms and relapse prevention, rather than targeting educational and vocational recovery, although engagement in work and education is a high priority for young people with early psychosis and reduces the social disability associated with the disorder. The aim of the present study is to explore the effects of Supported Employment and Education (SEE) following the Individual Placement and Support (IPS) model in people with early psychosis. The investigators compare treatment as usual (TAU) in an outpatient psychiatric setting to TAU plus SEE.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 184
• Est. completion date: March 31, 2025
• Est. primary completion date: December 31, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 16 Years to 35 Years

Eligibility

Inclusion Criteria:

• clinical diagnosis of early psychosis (DSM 5: schizophrenia spectrum and other psychotic disorders (297.1, 298.8, 295.4, 295.9, 295.7, 298.8, 298.9) within the last 5 years currently treated as outpatients
• sufficient linguistic and intellectual abilities to take part in the study
• interest in competitive employment or/and mainstream education
• written informed consent

Exclusion Criteria:

• Learning disability or mental retardation as well as insufficient German language abilities (< A2)
• physical or organic handicap that seriously impede work or educational functioning

Related Conditions & MeSH terms

• Disease
• Mental Disorders
• Psychotic Disorders
• Schizoaffective Disorder
• Schizophrenia
• Schizophrenia, Paranoid

Intervention

Other:
• Individual Placement and Support (IPS)
IPS is an evidence-based practice for helping people with severe mental illness to gain and maintain competitive employment or/and mainstream education with nine well defined key principles that can be reliably assessed by the IPS Fidelity Scale for Young Adults. Interventions range from engagement techniques (i.e. motivational interviewing) to individualized education/employment searches and from experience-based educational/employment assessment to benefits in counseling/work incentives planning.

Locations

Country	Name	City	State
Germany	Klinik für Psychiatrie und Psychotherapie Charité Campus Mitte	Berlin
Germany	Klinik für Psychiatrie, Psychotherapie und Psychosomatik Vivantes Klinikum am Urban	Berlin
Germany	Klinik für Psychiatrie, Universitätsklinikum Hamburg Eppendorf	Hamburg
Germany	Klinik für Psychiatrie und Psychotherapie, LMU Klinikum	München	Bayern
Germany	Klinik für Sozialpsychiatrie, Zentrum für Psychiatrie Reichenau	Reichenau	Baden Württemberg
Germany	Klinik für Psychiatrie, Psychotherapie und Psychosomatik II, Günzburg	Ulm	Bayern

Sponsors (1)

Lead Sponsor	Collaborator
Charite University, Berlin, Germany

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Primary outcome	The primary outcome is the binary indicator "Participating steadily for at least 50% of the 12 month follow-up in competitive employment or/and mainstream education". Days in competitive employment or/and mainstream education will be assessed monthly. Competitive employment is defined as jobs that anyone can apply for regardless of disability status. It comprises part and full-time positions, as well as seasonal or temporary positions depending upon the business needs of the employer. Mainstream education is defined in accordance with OECD as educational programs that are certificating or rather degree bearing and open to the general public.	12 months
Secondary	Length of competitive employment or/and mainstream education	Length of competitive employment or/and mainstream education (measured in days)	12 months
Secondary	Time to first competitive job/mainstream education	Time to first competitive job/mainstream education (measured in days)	12 months
Secondary	Monthly wages	Monthly wages (measured in Euro)	12 months
Secondary	Educational attainment	Educational attainment (measured in degrees/qualifications and ECTS points per semester)	12 months
Secondary	Social return on investment (SROI)	SROI will be computed as the ratio of 'benefits´ to 'total investment´ for each participant and is expressed as percentage. Participants' earnings in both competitive and non-competitive jobs, education, and apprenticeship hereby account as 'benefits´. 'Investments´ are defined as the total vocational program costs and total costs of mental health service per participant.	12 months
Secondary	Subjective quality of life	Subjective quality of life will be measured with the World Health Organization Quality of Life-BREF, a short version of the World Health Organization Quality of Life 100 scale. It's a self-report questionnaire which assesses 4 domains of quality of life: physical health, psychological health, social relationships, and environment. Participants express how much they have experienced the items in the preceding 4 weeks on a 5-point Likert scale ranging from 1 (not at all) to 5 (completely).Higher scores indicate a better quality of life.	12 months
Secondary	Psychopathology	Measured with the Positive and Negative Syndrome Scale (PANSS). The PANSS is a clinical interview rating the patient from 1 to 7 on 30 different symptoms. Ranges for the Positive Scale are 7 (minimum of symptoms) to 49 (maximum of symptoms), for the Negative Scale 7 (minimum of symptoms) to 49 (maximum of symptoms) and for the General Psychopathology Scale 16 (minimum of symptoms) to 112 (maximum of symptoms). Ratings are based on the interview as well as reports of family member and/or primary care workers. The interviewer must be trained to a standardized level of reliability.	12 months
Secondary	General substance abuse	General substance abuse (mininum use of 3 times per week per substance) is measured by a modified version of the Addiction Severity Index (ASI).	12 months
Secondary	Cannabis use	Cannabis use is specifically measured using the Daily Sessions, Frequency, Age of Onset and Quantity of Cannabis Use Inventory (DFAQ-CU).	12 months
Secondary	Relapse	Assessed according to DSM 5 relapse definition criteria.	12 months
Secondary	Hospitalization	Number of inpatient stays and duration of stays (measured in days) will be assessed.	12 months
Secondary	Functional impairment	Functional impairment with regard to occupational activity and participation will be assessed using a short version of the International Classification of Functioning, Disability, and Health (Mini-ICF-APP) instrument. The instruments consists of 13 capacity dimensions: adherence to regulations, planning and structuring of tasks, flexibility, applying expertise, capacity to judge and decide, endurance, assertiveness, contacts with others, teamwork capacity, self-care, mobility, proactivity and familiar and intimate relationships. Each dimension is rated from 0 (no impairment) to 4 (full impairment).	12 months
Secondary	Overall functional impairment	Overall level of functioning will be assessed using the Global Assessment of Functioning (GAF) scale. The GAF is a numeric scale to rate social, occupational and psychological functioning of an individual. Scores range from 1 (severely impaired) to 100 (extremely high functioning).	12 months